6 news items
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI
3 Jun 24
, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
KPTI
8 May 24
events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
8 May 24
, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
KPTI
24 Apr 24
Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can
q6hd 5bdl1skwyr4d7rjy30
KPTI
1 Apr 24
, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4
- Prev
- 1
- Next